We are live on ! Find out more
XLRN

Acceleron Pharma
XLRN

Delisted

XLRN was delisted on the 19th of November, 2021.

Back to rankings

62 hedge funds and large institutions have $527M invested in Acceleron Pharma in 2013 Q4 according to their latest regulatory filings, with 58 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 4 closing their positions.

New
Increased
Maintained
Reduced
Closed

4,397% more capital invested

Capital invested by funds: $11.7M → $527M (+$515M)

1,350% more first-time investments, than exits

New positions opened: 58 | Existing positions closed: 4

675% more funds holding

Funds holding: 8 → 62 (+54)

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

Holders
62
Holders Change
+54
Holders Change %
+675%
% of All Funds
1.8%
Holding in Top 10
3
Holding in Top 10 Change
+3
Holding in Top 10 Change %
% of All Funds
0.09%
New
58
Increased
2
Reduced
1
Closed
4
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
O
OrbiMed
New York
+$51.1M
2
Fidelity Investments
Fidelity Investments
Massachusetts
+$43.5M
3
DVC
Deer VII & Co
New York
+$26.7M
4
JP Morgan Chase
JP Morgan Chase
New York
+$18.5M
5
Franklin Resources
Franklin Resources
California
+$14.4M

Top Sellers

Rank Fund Capital Flow
1
Alyeska Investment Group
Alyeska Investment Group
Illinois
-$1.56M
2
ICAP
Independence Capital Asset Partners
Colorado
-$835K
3
MCM
Mazama Capital Management
Oregon
-$445K
4
FSA
Franklin Street Advisors
North Carolina
-$43.4K
5
SSG
Summit Securities Group
New York
-$1K
Name Holding Trade Value Shares
Change 		Change in
Stake
NFA
51
Nationwide Fund Advisors
Ohio
$194K +$118K +4,888 New
AIG
52
American International Group
New York
$169K +$103K +4,259 New
AllianceBernstein
53
AllianceBernstein
Tennessee
$127K +$77.2K +3,200 New
BJ
54
BlackRock Japan
Japan
$117K +$71.2K +2,948 New
SO
55
STRS Ohio
Ohio
$103K +$62.8K +2,600 New
SFU
56
Stonehage Fleming (UK)
United Kingdom
$72K +$43.8K +1,815 New
Wells Fargo
57
Wells Fargo
California
$64K +$38.7K +1,604 New
TRCT
58
Tower Research Capital (TRC)
New York
$55K +$33.8K +1,400 New
Barclays
59
Barclays
United Kingdom
$12K +$7.38K +306 New
BNP Paribas Financial Markets
60
BNP Paribas Financial Markets
France
$3.13K +$1.91K +79 New
Deutsche Bank
61
Deutsche Bank
Germany
$1K +$1.09K +45 New
Manulife (Manufacturers Life Insurance)
62
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$6 +$3.93K +163 New
Alyeska Investment Group
63
Alyeska Investment Group
Illinois
– -$1.56M -70,000 Closed
ICAP
64
Independence Capital Asset Partners
Colorado
– -$835K -37,557 Closed
MCM
65
Mazama Capital Management
Oregon
– -$445K -20,000 Closed
SSG
66
Summit Securities Group
New York
– -$1K -33 Closed
1 2
3

XLRN Hedge Fund Activity: Q4 2013 in Review

62 of the 3,445 institutional investors tracked by Wall St. Rank reported a position in Acceleron Pharma (XLRN) for Q4 2013, worth a combined $527M — up 4,397% from $11.7M a quarter earlier.

Buyers outnumbered sellers: 58 funds opened new XLRN positions and 4 closed out — a net gain of 54 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was OrbiMed, opening a new position worth an estimated $51.1M. The largest seller was Alyeska Investment Group, exiting entirely with an estimated $1.56M sold.

  • 62 institutional investors held Acceleron Pharma (XLRN) as of Q4 2013, up from 8 in Q3 2013.
  • Funds reported $527M of Acceleron Pharma stock for Q4 2013, up 4,397% quarter-over-quarter.
  • 58 funds opened new Acceleron Pharma positions in Q4 2013 and 4 closed out, a net change of +54 holders.
  • The largest Acceleron Pharma buyer in Q4 2013 was OrbiMed, an estimated $51.1M added.
  • The largest Acceleron Pharma seller in Q4 2013 was Alyeska Investment Group, an estimated $1.56M sold.

Based on aggregated 13F filings for Q4 2013.